Metabolic Crossroads: Kidneys, Liver Disease, and the Gut

9 Feb 2025 9 a.m. 10:30 a.m.
Amaltas Hall B101-A
GloriaAshuntantang Chair University of Bamenda, CameroonCameroon
Narayan Prasad Chair India
Dr Sree BhushanRaju Chair India

Session Description:
This session explores the interconnected relationships between the kidneys, liver, and gut. Topics include innovative treatments for hepatorenal syndrome and AKI in cirrhosis, such as the risks and benefits of terlipressin, and the role of gut microbiota in kidney disease. We will review the newly renamed entity of metabolic dysfunction-associated fatty liver disease (MAFLD) and its management and implications for kidney health. This session will also discuss the role of creatinine, cystatin C, measured GFR, and other methods to measure kidney function in patients with liver disease. 
Learning Objectives: 
1. Understand the latest evidence for the treatment of hepatorenal syndrome, AKI in cirrhosis, and MASLD. 
2. Examine the role of gut microbiota in the development and progression of kidney disease and explore potential therapeutic implications. 
3. List the limitations of conventional methods for measuring kidney function in liver disease and identify alternative methods.

Time Session
9 a.m.
9:18 a.m.
Hepatorenal Syndrome and New Treatments for AKI in Cirrhosis
Swetha RaniKanduri Speaker svetarani@gmail.comOchsner Health, New Orleans, LAUnited States
9:18 a.m.
9:36 a.m.
Do Gut Microbiota Contribute to Kidney Disease? If so, What Can We Do About it?
GrietGlorieux Speaker GRIET.GLORIEUX@UGent.beUGentBelgium
9:36 a.m.
9:54 a.m.
What Should Nephrologists Know About Metabolic Dysfunction-associated Fatty Liver Disease
Angela Yee-MoonWang Speaker angela.wang@duke-nus.edu.sgHong Kong/SingaporeSingapore
9:54 a.m.
10:12 a.m.
Measuring Kidney Function in Liver Disease - Pitfalls and Solutions
SmitaDivyaveer Speaker divyaveer.ss@gmail.comPOST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH, INDIAIndia
10:12 a.m.
10:30 a.m.
Q&A